Patent · US Expired

Insulin-like growth factor binding protein 3 (IGF-BP3) in treatment of p53-related tumors

US5840673A · kind A · utility

15Cited by
1References
4Claims
0Family size

Assignee

Inventors

Key dates

Filing dateSep 12, 1996
Grant dateNov 24, 1998
Priority date
Expiry dateSep 12, 2016

Classification

  • Technology area (CPC A)Human Necessities
  • CPC primaryA61P43/00
  • WIPO fieldPharmaceuticals
  • WIPO sectorChemistry

Abstract

Methods of treating p53-related tumors by administering (1) a modulator of IGF-BP3, wherein the modulator upregulates IGF-BP3 expression or activity, (2) IGF-BP3 itself, or (3) an expression vector comprising a nucleotide sequence encoding IGF-BP3. In the latter method, the IGF-BP3 nucleotide sequence may also be operatively linked to an inducible promoter or enhancer, wherein the method further comprises administering an inducer capable of initiating or upregulating expression of the protein. Furthermore, any of the foregoing methods may include as an additional step administration of a cytotoxic agent. These methods are specific examples of a broader method: treatment of p53-related tumors by inhibiting the binding of IGF to IGFR.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.